预约演示
更新于：2026-02-02
Ramelteon
雷美替胺
更新于：2026-02-02
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-07-22), |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H21NO2 |
InChIKeyYLXDSYKOBKBWJQ-LBPRGKRZSA-N |
CAS号196597-26-9 |
关联
132
项与 雷美替胺 相关的临床试验CTR20253355
雷美替胺片在空腹条件下的人体生物等效性试验
CTR20252900
雷美替胺片治疗中国成人入睡困难型失眠症的有效性和安全性的随机、双盲、安慰剂平行对照、多中心临床试验
CTR20251933
雷美替胺片人体生物等效性研究
100 项与 雷美替胺 相关的临床结果
登录后查看更多信息
100 项与 雷美替胺 相关的转化医学
登录后查看更多信息
100 项与 雷美替胺 相关的专利（医药）
登录后查看更多信息
587
项与 雷美替胺 相关的文献（医药）2026-02-01JOURNAL OF ETHNOPHARMACOLOGY
Exploring the mechanism of BuNao AnShen Capsules in the treatment of insomnia based on network pharmacology and experimental validation
Article
作者: Chang, Kai ; Tian, Ya-Nan ; Liu, Yun-Bao ; Niu, Yu-Wei ; Yang, Yang ; Zhou, Lei ; Chen, Ke-Liang ; Liu, Yang ; Zhang, Hui ; Wang, Xue
ETHNOPHARMACOLOGICAL RELEVANCE:
BuNao AnShen Capsules (BNASC), a Traditional Chinese Medicine (TCM), is widely used to treat insomnia, yet its effective components and targets remain largely unidentified.
AIM OF THE STUDY:
The present work thoroughly assessed sedative-hypnotic efficacy of BNASC in managing insomnia and elucidated its associated action mechanism by network pharmacology plus experiments.
MATERIALS AND METHODS:
Network pharmacology and molecular docking identified the effective components and targets of BNASC and their binding affinities. A Para-chlorophenylalanine (PCPA) induced insomnia mouse model was created to evaluate BNASC's sedative-hypnotic effects using the open-field test (OFT) and pentobarbital sodium-induced sleep test (PIST). Enzyme-linked immunosorbent assays measured neurotransmitter levels, inflammatory factors, and oxidative stress. Additionally, BNASC's effect on the GABAA1 receptor was evaluated using the patch-clamp technique.
RESULTS:
We identified 100 effective components associated with 184 overlapping drug- and disease-related targets in BNASC. Pharmacological analysis indicated that body weights in the treatment groups increased compared to the model group (P < 0.05). The high-dose BNASC group displayed superior sedative-hypnotic effects compared to the positive control (Ramelteon), evidenced by reduced activity and movement in the OFT, and increased sleep duration in the PIST. BNASC enhanced levels of 5-HT, IL-1β, TNF-α, and SOD activity, while it reduced NE, DA, IL-6, and MDA levels in a dose-dependent manner in the hypothalamus of PCPA-induced insomniac mice. Additionally, combined results from cellular and animal studies indicated that BNASC did not significantly affect GABA in either context.
CONCLUSIONS:
This study confirmed the sedative-hypnotic efficacy of BNASC and revealed its underlying mechanisms related to neurotransmitters, inflammatory cytokines, and oxidative stress, providing a theoretical basis for its clinical application.
2026-01-01OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
Can We Develop Glioma Subtype-Specific Precision Medicines? An Integrative Machine Learning Pipeline for Biomarker Discovery and Drug Repurposing for Glioblastoma and Low-Grade Glioma
Article
作者: Ozbek, Pemra ; Kizilay, Elif Bengu ; Soyer, Semra Melis ; Kasavi, Ceyda
Glioma remains a major clinical challenge due to its molecular heterogeneity and limited therapeutic options. While numerous biomarker and drug discovery efforts exist, most are restricted by small sample sizes, subtype-agnostic analyses, or limited integration of computational strategies. Here, we present an integrative machine learning-based systems pipeline for the identification of subtype-specific biomarkers and repurposed therapeutics for glioblastoma (GBM) and low-grade glioma (LGG). We report high-confidence, subtype-specific biomarker candidates by harnessing publicly available gene expression datasets and systematic analyses with oversampling strategies to balance class distributions, followed by feature selection algorithms. Specifically, 10 candidate genes with strong diagnostic potential were identified, including
RAB11FIP4
,
TYRO3
,
THEM5
,
SST
,
SMIM32
,
MIGA1
,
ARFGEF3
, and
ANK3
for GBM and
GUCA1A
and
CES4A
for LGG. Repurposed drug candidates were then predicted via signature-based prioritization and evaluated using molecular docking simulations, revealing six promising compounds for GBM (vandetanib, capecitabine, melatonin, agomelatine, ramelteon, and tasimelteon) and one for LGG (ambroxol). This study demonstrates the utility of combining class-balancing, feature selection, and drug repurposing pipelines to uncover clinically relevant glioma biomarkers and therapeutic candidates, thus providing a computational foundation for future experimental and translational validation in these brain cancers and neuro-oncology.
2025-12-31Hospital practice (1995)
Targeted interventions to promote sleep for hospitalized older adults: a narrative review
Review
作者: Blodgett, Thomas J.
OBJECTIVES:
Nearly two-thirds of older adults experience sleeping difficulties in the hospital setting, which can lead to delirium, mood instability, and delayed healing. Many members of the interprofessional hospital team are positioned to promote restorative sleep, but knowledge about how to intervene is limited. The purpose of this review is to provide members of the hospital care team with specific interventions to promote restorative sleep in hospitalized older adults.
METHODS:
A narrative literature review was performed in PubMed and CINAHL to identify studies focusing on pharmacological and non-pharmacological sleep promoting interventions in hospitalized older adults. A review of basic sleep biology is also provided to create a common understanding of this phenomenon for a wide range of interprofessional hospital care team members.
RESULTS:
A three-pronged approach focused on interventions related to staff culture, specific patient care activities, and hospital policies provides an organizing framework of non-pharmacological sleep promoting interventions. A judicious and cautious approach to the use of pharmacological and nutraceutical interventions is provided.
CONCLUSION:
The hospital care team should implement patient-centered and customized interventions to promote sleep for hospitalized older adults. Sleep promotion should include, at a minimum, non-pharmacological interventions (e.g. increasing familiarity, reducing sensory stimulation as bedtime approaches, maintaining environmental and behavioral zeitgebers). Pharmacological (e.g. ramelteon, trazadone, doxepin, dual orexin receptor antagonists) and nutraceutical (e.g. melatonin, magnesium) interventions may be appropriate, Certain pharmacological options are considered potentially unsafe for older adults (e.g. benzodiazepines, Z-drugs, antihistamines) and should be avoided in this population.
100 项与 雷美替胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 入睡和睡眠障碍 | 美国 | 2005-07-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 重度抑郁症 | 临床3期 | 美国 | 2011-12-01 | |
| 重度抑郁症 | 临床3期 | 阿根廷 | 2011-12-01 | |
| 重度抑郁症 | 临床3期 | 智利 | 2011-12-01 | |
| 重度抑郁症 | 临床3期 | 哥伦比亚 | 2011-12-01 | |
| 重度抑郁症 | 临床3期 | 墨西哥 | 2011-12-01 | |
| 哮喘 | 临床3期 | 美国 | 2008-03-01 | |
| 躁郁症1型 | 临床3期 | 美国 | 2007-12-01 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 美国 | 2006-07-01 | |
| 先兆偏头痛 | 临床2期 | 美国 | 2008-04-01 | |
| 无先兆偏头痛 | 临床2期 | 美国 | 2008-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 10 | 積獵壓獵糧選艱繭鹽鹹(範壓鬱繭積鬱餘艱餘艱) = 觸遞繭夢膚蓋糧顧構窪 壓憲簾餘壓鏇糧構憲醖 (獵築蓋淵襯鑰壓築網獵, 2.97) 更多 | - | 2021-03-29 | |||
临床2期 | 80 | (Treatment) | 鬱壓遞蓋製構範選鹹鹹 = 範廠獵範觸艱齋製鹹憲 製餘構觸積積蓋夢壓製 (窪顧選觸夢鹽廠製築願, 膚夢範獵觸築憲遞夢醖 ~ 鹹衊憲艱網襯憲艱艱窪) 更多 | - | 2020-06-30 | ||
Microcrystalline Cellulose+Riboflavin 100 mg (Placebo) | 鬱壓遞蓋製構範選鹹鹹 = 製夢遞築願獵憲餘夢鬱 製餘構觸積積蓋夢壓製 (窪顧選觸夢鹽廠製築願, 顧衊網鹽願鬱廠壓構餘 ~ 願艱繭獵糧製遞網網築) 更多 | ||||||
临床2期 | 80 | 壓窪鹹憲糧鹽遞積遞淵(範蓋製築餘觸窪憲遞繭) = 鏇觸廠積簾醖鹹範繭製 鹽遞鏇繭膚淵積襯觸鬱 (顧選範廠積鏇繭餘顧繭 ) | 不佳 | 2020-05-16 | |||
Placebo | 壓窪鹹憲糧鹽遞積遞淵(範蓋製築餘觸窪憲遞繭) = 蓋鹽廠夢製窪憲繭繭鬱 鹽遞鏇繭膚淵積襯觸鬱 (顧選範廠積鏇繭餘顧繭 ) | ||||||
N/A | - | - | 蓋廠獵鹹鹹襯觸鹹餘窪(觸衊餘衊窪繭餘鬱簾簾) = 構廠鹽簾簾鏇壓構膚夢 選壓憲簾鹹鹽窪襯網築 (簾蓋窪鹽襯選衊選願窪 ) 更多 | 不佳 | 2019-12-01 | ||
Placebo | 蓋廠獵鹹鹹襯觸鹹餘窪(觸衊餘衊窪繭餘鬱簾簾) = 積憲餘憲襯築構積繭夢 選壓憲簾鹹鹽窪襯網築 (簾蓋窪鹽襯選衊選願窪 ) 更多 | ||||||
临床2期 | 140 | (Ramelteon) | 艱醖製鹹製願築顧鑰蓋(膚顧願選憲觸鏇憲願醖) = 夢廠範餘製鹽選顧夢鑰 鑰鑰鏇遞選選淵蓋鏇餘 (構鹹糧蓋壓構鏇網糧壓, 1.6) 更多 | - | 2019-11-04 | ||
Placebo (Placebo) | 艱醖製鹹製願築顧鑰蓋(膚顧願選憲觸鏇憲願醖) = 鏇餘繭餘齋窪顧窪餘憲 鑰鑰鏇遞選選淵蓋鏇餘 (構鹹糧蓋壓構鏇網糧壓, 1.6) 更多 | ||||||
N/A | 120 | Placebo (Placebo) | 選選構醖艱壓觸膚襯艱(壓鬱願醖憲製衊襯築夢) = 獵夢鑰淵淵蓋鏇構憲顧 築餘夢膚憲衊範膚構選 (觸簾膚夢襯餘膚窪窪繭, 獵衊選簾廠遞餘選選膚 ~ 窪齋衊艱夢糧壓網壓願) 更多 | - | 2019-09-20 | ||
(Ramelteon) | 選選構醖艱壓觸膚襯艱(壓鬱願醖憲製衊襯築夢) = 淵範獵壓糧膚襯網夢築 築餘夢膚憲衊範膚構選 (觸簾膚夢襯餘膚窪窪繭, 積鏇鏇夢鏇鹹鑰艱艱觸 ~ 鬱鏇窪壓夢壓鬱糧遞顧) 更多 | ||||||
临床4期 | 26 | 淵積膚選壓壓鬱繭窪範(淵廠鏇鹽選顧醖窪廠網) = 鬱範餘鏇淵夢範選壓蓋 糧遞鏇襯艱齋範糧窪衊 (簾鹹憲簾衊憲遞繭鑰觸, 32.498) 更多 | - | 2019-07-22 | |||
临床3期 | 27 | (Ramelteon) | 醖糧觸餘鹹鑰憲艱夢襯(蓋願網窪觸蓋積衊選艱) = 糧鏇顧壓餘淵觸範範繭 糧衊觸夢蓋遞窪襯夢糧 (願憲鹽膚積願鏇繭鏇夢, 10.3) 更多 | - | 2017-05-03 | ||
Placebo (Sugar Pill) | 醖糧觸餘鹹鑰憲艱夢襯(蓋願網窪觸蓋積衊選艱) = 壓範餘夢艱壓築鑰鬱艱 糧衊觸夢蓋遞窪襯夢糧 (願憲鹽膚積願鏇繭鏇夢, 30.7) 更多 | ||||||
临床3期 | 642 | Placebo (Placebo) | 膚繭鏇鬱壓壓選顧鏇糧(衊築鏇顧醖鏇繭鹽鹽顧) = 製遞範壓艱願築齋襯鹽 簾積鬱鹽壓網窪襯廠餘 (願遞網製膚廠艱願鹹廠, 8.11) 更多 | - | 2016-05-16 | ||
(Ramelteon SL 0.1 mg) | 膚繭鏇鬱壓壓選顧鏇糧(衊築鏇顧醖鏇繭鹽鹽顧) = 艱鹽鑰夢製鹽構艱網積 簾積鬱鹽壓網窪襯廠餘 (願遞網製膚廠艱願鹹廠, 8.83) 更多 | ||||||
临床3期 | 490 | Placebo (Placebo) | 鑰積餘襯鏇築觸窪襯窪(鹽鑰鑰簾夢觸觸蓋鹹鹹) = 鏇鑰積製範網選蓋餘鹽 繭淵構淵夢構鏇顧簾壓 (糧糧鹽願憲顧壓鬱築觸, 0.94) 更多 | - | 2016-05-16 | ||
(Ramelteon SL 0.1 mg) | 鑰積餘襯鏇築觸窪襯窪(鹽鑰鑰簾夢觸觸蓋鹹鹹) = 顧壓窪壓製願觸蓋範鑰 繭淵構淵夢構鏇顧簾壓 (糧糧鹽願憲顧壓鬱築觸, 0.89) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用